Myoferlin, an understudied oncogene

Myoferlin, an understudied oncogene

The team form Metastasis Research Laboratory (GIGA Cancer, ULg) has recently demonstrated that myoferlin regulates epidermal growth factor signaling in breast cancer by affecting intracellular handling of the activated epidermal growth factor receptor. Motivated by these results, the ULg researchers in collaboration with the Department of Molecular Pharmacology and Oncology (Gunma University Graduate School of Medicine, Japan) have investigated myoferlin expression in triple-negative breast cancer cells (TNBC). Their data show that myoferlin is overexpressed in the majority of TNBC cells, both at mRNA and protein level.

Intrigued by these findings the investigators assessed proteomics, metabolomics and ultrastructural changes following myoferlin suppression. They found that myoferlin is an essential component of the cellular endosomal machinery, regulating fatty acid household, mitochondrial function and, hence, global metabolism in TNBC cells.

High levels of myoferlin conferred metabolic flexibility to TNBC cells, allowing them to adapt to hostile environments and, hence, increase their metastatic potential. The significance of this observation was further supported by clinical data, showing that TNBC patients, whose tumors overexpress myoferlin, have worst distant metastasis-free and overall survivals. This novel insight into myoferlin function establishes an important link between vesicle traffic, cancer metabolism and progression, offering new diagnostic and therapeutic concepts to develop treatments for TNBC patients.

Related articles

PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

Liège (Belgium), 21st January 2019. PDC*line Pharma is delighted to announce, that the company is now accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for the Quality Control and Release activities of its anticancer agent PDC*lung, intended for the treatment of patients with lung cancer.  PDC*line Pharma is developing a new

Read more
PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

First Congress in Health Simulation

The Medical Simulation Center of the University of Liège organizes its first congress in Health Simulation: “Towards evidence-based simulation”. Event will be held on Thursday, March 28th, 2019 in the faculty of medicine amphitheatres of Liège University, located on Sart-Tilman campus. Several themes will be discussed: Evidence-based Innovations and advances in simulation Medical education –

Read more
First Congress in Health Simulation

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials